Literature DB >> 7905505

Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression.

J S Dayton1, T Lindsten, C B Thompson, B S Mitchell.   

Abstract

Inosine monophosphate dehydrogenase (IMPDH) catalyzes the first step in the formation of guanine ribonucleotides from inosine monophosphate and the activity of this enzyme appears to be essential for cell proliferation. Inhibitors of IMPDH have been demonstrated to be effective immunosuppressive agents and to inhibit T cell activation in vitro. IMPDH activity results from the expression of two different genes (types I and II) that encode protein subunits of identical size with 84% amino acid identity. To determine the relative contribution of the expression of these two genes to T cell activation, we have examined the effects of T cell stimulation on IMPDH activity, mRNA levels, and protein. The stimulation of isolated peripheral blood CD28+ T cells with PMA and ionomycin causes a 15-fold increase in IMPDH activity over a 72-h period. This is associated with a 10-fold increase in type II mRNA levels at 48 h. Type I mRNA is expressed at very low levels in resting T cells, but increases 10-fold by 24 h after stimulation. The type I cDNA probe also detects a second larger mRNA species of 4.0 kb that is not detectable in a variety of normal tissues or in a panel of leukemic cell lines. RNase protection assays using RNA probes corresponding to the entire coding region of the type I enzyme reveal a single protected fragment, demonstrating that the 4.0-kb message is the result of alternate splicing in the 5' or 3' untranslated regions or the use of an alternative polyadenylation site. Western blot analysis demonstrates a concomitant increase in total IMPDH protein on T cell activation, although posttranslational modifications do not allow the distinction between type I and type II on isoelectric focusing gels. We conclude that the induction of both type I and type II IMPDH contribute significantly to the T cell proliferative response. Both enzymes therefore should be considered important targets for immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905505

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Regulation of an IMP dehydrogenase gene and its overexpression in drug-sensitive transcription elongation mutants of yeast.

Authors:  R J Shaw; J L Wilson; K T Smith; D Reines
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

Review 2.  IMP dehydrogenase: structure, mechanism, and inhibition.

Authors:  Lizbeth Hedstrom
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

3.  T cell activation triggers reversible inosine-5'-monophosphate dehydrogenase assembly.

Authors:  Krisna C Duong-Ly; Yin-Ming Kuo; Matthew C Johnson; Joy M Cote; Justin M Kollman; Jonathan Soboloff; Glenn F Rall; Andrew J Andrews; Jeffrey R Peterson
Journal:  J Cell Sci       Date:  2018-09-05       Impact factor: 5.285

4.  Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Authors:  T D Colby; K Vanderveen; M D Strickler; G D Markham; B M Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Phenotypic characterization of a large family with RP10 autosomal-dominant retinitis pigmentosa: an Asp226Asn mutation in the IMPDH1 gene.

Authors:  Petra Kozma; Dianna K Hughbanks-Wheaton; Kirsten G Locke; Garry E Fish; Anisa I Gire; Catherine J Spellicy; Lori S Sullivan; Sara J Bowne; Stephen P Daiger; David G Birch
Journal:  Am J Ophthalmol       Date:  2005-10-07       Impact factor: 5.258

6.  Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene.

Authors:  J J Gu; S Stegmann; K Gathy; R Murray; J Laliberte; L Ayscue; B S Mitchell
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 7.  Pharmacological targeting of allergen-specific T lymphocytes.

Authors:  Peter A Tauber; Winfried F Pickl
Journal:  Immunol Lett       Date:  2017-03-18       Impact factor: 3.685

8.  Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study.

Authors:  Sara Bremer; Nils T Vethe; Helge Rootwelt; Pål F Jørgensen; Jean Stenstrøm; Hallvard Holdaas; Karsten Midtvedt; Stein Bergan
Journal:  J Transl Med       Date:  2009-07-27       Impact factor: 5.531

9.  Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice.

Authors:  Jing Jin Gu; Amy K Tolin; Jugnu Jain; Hai Huang; Lalaine Santiago; Beverly S Mitchell
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 10.  Pediatric liver transplantation.

Authors:  Marco Spada; Silvia Riva; Giuseppe Maggiore; Davide Cintorino; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.